skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Reed

Pennsylvania, USA

+20 year(s) experience

Reed Miller
Reed focuses on new technology development, especially the conduct and regulation of clinical trials of cardiovascular devices. He also contributes to Medtech Insight's commercial coverage, ranging from the newest start-ups to the largest established conglomerates.
Reed, deputy editor for Commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. Since his primary focus has been clinical trials and new product development, Reed has covered innumerable FDA advisory panel meetings and Medicare coverage decisions.

Mixed into his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he became deputy editor of Medtech Insight, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization.

Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.

 

Analyst Articles

Articles by Kevin

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Pharma Can Reset Reputation In Pandemic Says Novartis CEO

    Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.

    Topic Coronavirus

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Another Alzheimer's Setback As Roche And Lilly Drugs Fail

    As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.

    Topic Alzheimer's Disease

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    The Healthcare World According To Andrew Witty

    The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies can lead to simpler, more cost-effective health systems.

    Topic digital-health

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    J&J's Spravato Set For EU Launches Soon

    Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.

    Topic drug-approval drug-development-landscape

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Webinar: Q1 2019 Sales and Earnings

    Scrip editors will dissect Q1 sales and earnings reports of top pharma companies and focus on key trends, developments, and projected future impact.

  • Scrip: 世界の医療用医薬品&製薬産業に関するニュース

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    Bayer Bosses Beg Risk-Averse Europe To Rethink

    The German group believes it is going to be at the forefront of development in the cell and gene therapy space but is worried that Europe is failing to recognize the value that the pharma industry and its new technologies can create for society.

    Topic cell-and-gene-therapy